SynthesisClinical neuroradiology2025
Modulating Cognitive Function with Antihypertensive Medications: a Comprehensive Systematic Review On FMRI Studies.
Synthesis in Clinical neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Electroacupuncture treatment can improve cognitive impairment in spontaneously hypertensive rats: a preliminary DTI study.Frontiers in neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertension (HTN) is a prevalent cardiovascular condition associated with cognitive impairments, including memory deficits and attention lapses. Understanding the neural mechanisms underlying HTN-related cognitive dysfunction is crucial for optimizing treatment strategies.
methodA systematic review was conducted to explore the impact of antihypertensive medications on cognition, focusing on memory, attention, and emotion processing using functional magnetic resonance imaging (fMRI). Searches were performed in PubMed and Scopus up to March 10, 2024, with no language restrictions.
resultsA total of 108 articles were identified, of which 12 systematic reviews and meta-analyses met the inclusion criteria. Included studies investigated various antihypertensive drugs, including losartan, propranolol, spironolactone, and telmisartan, and their effects on cognitive processes. Losartan improved negative memory encoding and facilitated fear extinction via hippocampal and prefrontal modulation. Propranolol disrupted fear reconsolidation and reduced emotional memory retrieval, affecting the amygdala and hippocampus. Spironolactone prevented stress-induced memory shifts in the amygdala. Findings indicated distinct impacts of these medications on memory encoding, fear extinction, and stress-induced memory modulation, as evidenced by alterations in neural activity patterns observed on fMRI.
conclusionAntihypertensive medications, such as losartan and propranolol, demonstrate potential in modulating memory, fear-related memory reconsolidation, and stress-induced memory modulation, highlighting their therapeutic implications for conditions like posttraumatic stress disorder (PTSD) and anxiety disorders. This review underscores the importance of fMRI studies in elucidating the neural correlates of HTN-related cognitive impairments and optimizing treatment approaches.
Indexed as
Identifiers
39833317What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.